Project: Sialylated antigens as immune tolerance inducers: an innovative therapeutic vaccine for MS.
SIAGEN-MS will develop a therapeutic vaccine against Multiple Sclerosis (MS) by modification of myelin-derived peptides through sialylation. The Eurostars project will deliver 1) A sialylated antigen-based therapeutic vaccine that is able to target dendritic cells and/or microglia, 2) in vivo evidence that the therapeutic vaccine is able to slow and inhibit progress of MS, 3) initiated preclinical toxicology and safety assessments.
| Acronym | SIAGEN-MS (Reference Number: 9059) |
| Duration | 01/01/2015 - 01/01/2018 |
| Project Topic | Biological Sciences / Technologies |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 1 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 19340 | DC4U B.V. | Coordinator | Netherlands |
| 19341 | Stichting VU-VUmc | Partner | Netherlands |
| 19342 | University of Bern | Partner | Switzerland |
| 19343 | piCHEM Forschungs- und Entwicklungs GmbH | Partner | Austria |
| 19344 | MD Biosciences GmbH | Partner | Switzerland |